Boston, MA -- (SBWIRE) -- 01/13/2016 -- Psoriatic arthritis is a chronic inflammatory disease that affects the distal joints in the body and may also affect the back and sacroiliac joints of the pelvis. The global market for psoriatic arthritis is expected to witness moderate growth during the forecast period and factors like the increase in penetration of biologic therapies are expected to augment the prospects for growth in this market. Additionally, the recent launch of products like Otezla and Stelara is also expected to boost market growth during the forecast period, resulting in its moderate CAGR of nearly 5% by 2019.

In this market research report, Technavio analysts estimate the Americas to account for more than 40% of the total market share by 2019. High market dominion of this region can be attributed to factors such as the increase in public awareness and the growing preference for biologic drugs.

Get More Details on this Report and a Full Table of Contents at Global Psoriatic Arthritis Market 2015-2019

Segmentation by mechanism of action and analysis of: TNF inhibitors, PDE4 inhibitors, & interleukin blockers

The TNF inhibitors aid in suppressing the inflammatory response in the patient's body. These inhibitors are used to manage diseases like rheumatoid arthritis, psoriatic arthritis, psoriasis, inflammatory bowel disease, and seronegative spondyloarthropathies. Moreover, its ability to use a targeted mechanism to treat most of the inflammatory and autoimmune diseases is primarily responsible for its high market share of almost 80% by 2019.

The report offers an analysis of each of the following segments and discusses its impact on the overall market growth -

-TNF inhibitors
-PDE4 inhibitors
-Interleukin blockers
-Others

Segmentation by type of disease and analysis of: mild, moderate, & severe psoriatic arthritis

The mild psoriatic arthritis segment accounts for more than 60% of all the diagnosed cases and is the most common type of psoriatic arthritis in patients across the globe. This condition affects less than four joints in the body and is also known as oligoarticular arthritis.

The report offers an analysis of each of the following segments and discusses its impact on the overall market growth -

-Mild psoriatic arthritis
-Moderate psoriatic arthritis
-Severe psoriatic arthritis

Competitive landscape and key vendors: Abbvie, Amgen, Janssen Pharmaceuticals

This market is primarily dominated by large vendors due to their extensive product portfolios. The company that manufactures and markets a drug that can treat psoriatic arthritis, and also exhibit a high safety and efficacy profile, is expected to gain a competitive advantage over its rivals during the forecast period.

Leading vendors in this market are -

-Abbvie
-Amgen
-Janssen Pharmaceuticals
-Celgene
-UCB

Other prominent vendors analyzed in this market study are Alder Biopharmaceuticals, Biogen Idec, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, F. Hofffmann-La Roche, Kyowa Hakko Kirin, Merck, Novartis, Pfizer, Sandoz, Sun Pharmaceuticals, and Takeda Pharmaceutical.

Key questions answered in the report include

-What will the market size and the growth rate be in 2019?
-What are the key factors driving the psoriatic arthritis market?
-What are the key market trends impacting the growth of the psoriatic arthritis market?
-What are the challenges to market growth?
-Who are the key vendors in the psoriatic arthritis market?
-What are the market opportunities and threats faced by the vendors in the psoriatic arthritis market?
-Trending factors influencing the market shares of APAC, EMEA, and the Americas?
-What are the key outcomes of the five forces analysis of the psoriatic arthritis market?

Technavio also offers customization on reports based on specific client requirement.

Related reports

-Global Rheumatoid Arthritis Drugs Market 2014-2018

Companies Mentioned in this Report: Hoffmann-La Roche, Eli-lilly, Sanofi, Otsuka Holdings, Novartis, Amgen, Boston Biomedical, AROG Pharmaceuticals, ARIAD Pharmaceuticals, Roche, Merck, Eli Lilly, AB Science, Galena Biopharma, AstraZeneca, Taiho Oncology, Samumed, Ipsen Biopharmaceuticals, Eddingpharm, Tekmira Pharmaceuticals, Bristol-Myers Squibb, Gilead Sciences, ASLAN Pharmaceuticals, Five Prime, Array Biopharma, BIND Therapeutics, Boehringer Ingelheim, Daiichi-Sankyo, Bayer HealthCare, Celgene.

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

-Systemic Juvenile Idiopathic Arthritis (SJIA) Global Clinical Trials Review, H2, 2015
-Idiopathic Juvenile Arthritis (Still's Disease) Global Clinical Trials Review, H2, 2015
-Rheumatoid Arthritis Therapeutics in Asia-Pacific Markets to 2021 - Novel IL-6 and JAK Inhibitors to Stimulate Moderate Growth Despite Brand Erosion of Blockbuster Anti-TNFs
-Psoriatic Arthritis - Pipeline Review, H1 2015
-Rheumatoid Arthritis - Pipeline Review, H1 2015